Karine Tawagi MD
@DrKarineTawagi
GU Oncologist | APD | 🇨🇦 GU & NOLA Heme/Onc Alumni | Interested in GU, Immuno Onc & Med Ed | @ASCO Featured Voice | @TwoOncDocs podcast
ID:1112755822113841153
01-04-2019 16:37:16
557 Tweet
1,6K Takipçi
990 Takip Edilen
We are back this week with Tom Powles & Brian Rini, MD diving into metastatic RCC!
We discuss risk stratification, their differing opinions around cytoreductive nephrectomy, 1L tx & sequencing, pearls regarding sarcomatoid, non-clear-cell RCC & tips for trainees Uromigos
Fun PrecisCa meeting leaders and innovators in oncology and presenting a complex case on castrate resistant metastatic prostate cancer🤓🔬 #Oncology #cancer #prostatecancer #guoncology
#ASCO24 is 4 weeks away! Excited to dive into key studies and their clinical impact at Advancements in Oncology!
InPerson: June 1st, 2024 with Margaret Gatti-Mays MD MPH FACP Dr. Cathy Eng Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation Karine Tawagi MD we will navigate our changing Rx Landscape!
Register: [email protected]…
We are so excited to have the @uromigos back for kidney cancer board review & 2024 updates
First up with Localized RCC discussing risk factors, who needs genetic testing, who qualifies for adjuvant therapy…& who’s a faster swimmer btw Brian Rini, MD & Tom Powles
Very happy to share our study published Journal of Clinical Oncology ! ascopubs.org/doi/full/10.12…
➡️Patients with mUC with NECTIN4 amplifications (occurring in app. 25%) show remarkable responses to single-agent EV, with a 96% objective response rate compared to 32% in non-amplified cases. NECTIN4…
A glimpse of many exciting Med Ed & Professional Dev abstracts to be presented at the ASCO Annual Meeting this year, including 1 oral & 3 posters from our collaboration btw TwoOncDocs & The Fellow On Call
Ronak H. Mistry, DO Samantha Armstrong Karine Tawagi MD Vivek Patel, MD Daniel Hausrath
KN564: Pembro was approved for high risk adj RCC in Nov 2021 based off this study. Now on NEJM w/ OS benefit.
- DFS HR: 0.72 and OS HR: 0.62
- At 48 mos, OS 91.2% w/ #Pembrolizumab vs 86%
- Toni Choueiri, MD Tian Zhang, MD, MHS Tom Powles et al. 👏👏👏
#OncTwitter #MedTwitter #GUSM
In this week’s episode, Dr. Larry Einhorn discusses the history of testicular cancer Tx, writing board review Qs for the ABIM, treating Lance Armstrong, staging, mediastinal tumors & seminomas
podcasts.apple.com/us/podcast/two…
If AFP is elevated, what is the most likely diagnosis?
April marks #TesticularCancer Awareness Month 💜
We are so excited to welcome Dr. Larry Einhorn from IU Simon Comprehensive Cancer Center, a true legend when it comes to the treatment of Germ Cell Tumors, for our next 2 episodes!
He shares board review pearls & words of wisdom for trainees.
💫📢🎉It’s our immense pleasure to introduce you to the ASCO #IMG CoP - Program Directors Committee. Our goal is to enhance #IMG 's journey and foster a nurturing environment during hem/onc fellowship!
ASCOTECAG Martina Murphy, MD Arthi Sridhar Noha N. Soror, MD, MSc. 𓂀 Karine Tawagi MD OncoAlert
Excited to welcome those in the Chicago area to the next GU Rounds Ivy Room Chicago!
Jam packed agenda +dinner w/ exciting cross-disciplinary discussions in prostate, bladder, renal cancers.
Still a few spots left to sign up @ gurounds.com for this April 3 CME event
Sia Daneshmand, MD, and Karine Tawagi, MD, join Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for non–muscle-invasive bladder cancer. #blcsm | Oncology Brothers Sia Daneshmand, M.D. Karine Tawagi MD
cancernetwork.com/view/treatment…
Oncology Brothers Karine Tawagi MD Sia Daneshmand, M.D. CancerNetwork® Bijoy Telivala Yakup Ergün Andrea Apolo, M.D. Santhosh Ambika Amanda Nizam, MD Petros Grivas Shilpa Gupta Enrique Grande Tom Powles Paulo G Bergerot Very nice, although please note radical cystectomy is not the only standard of care for MIBC. It’s just that we’re biased towards surgery in the USA. Bladder preservation is also NCCN category 1 and should not be biased towards frail.